Table 1. Top drug combinations, in rank order.
| combination | number observationsa | agent 1 targetb | agent 2 targetb | Rankc |
|---|---|---|---|---|
| Flavopiridol & JQ1 | 11 | CDK | Bromodomain | 1 |
| Flavopiridol & PF-431396 | 10 | CDK | FAK/PYK2 | 2 |
| Gemcitabine & JQ1 | 10 | nucleoside analog | Bromodomain | 2 |
| GSK1120212 & PF-431396 | 9 | MEK1 & 2 | FAK/PYK2 | 3 |
| JQ1 & MLN-4924 | 9 | Bromodomain | Neddylation | 3 |
| SB225002 & YM155 | 9 | CXCR2 | Survivin | 3 |
| Foretinib & GDC-0941 | 8 | MET & AXL &… | PI3K | 4 |
| GDC-0941 & GSK1120212 | 8 | PI3K | MEK1 & 2 | 4 |
| JQ1 & SN-38 | 8 | Bromodomain | Topoisomerase | 4 |
| MLN-4924 & PF-431396 | 8 | Neddylation | FAK/PYK2 | 4 |
| AZD-8055 & SN-38 | 7 | mTOR-specific | Topoisomerase | 5 |
| BI-2536 & JQ1 | 7 | Polo-like kinase | Bromodomain | 5 |
| Dasatinib & Foretinib | 7 | Abl & Src | MET & AXL &… | 5 |
| Flavopiridol & GSK1120212 | 7 | CDK | MEK1 & 2 | 5 |
| Foretinib & GSK1120212 | 7 | MET & AXL &… | MEK1 & 2 | 5 |
| GDC-0941 & PF-431396 | 7 | PI3K | FAK/PYK2 | 5 |
| MLN-4924 & SN-38 | 7 | Neddylation | Topoisomerase | 5 |
| SB225002 & SN-38 | 7 | CXCR2 | Topoisomerase | 5 |
| SN-38 & Simvastatin | 7 | Topoisomerase | HMGCoA Reductase | 5 |
| AZD-7762 & SN-38 | 6 | Chk1/2 | Topoisomerase | 6 |
| AZD-8055 & Foretinib | 6 | mTOR-specific | MET & AXL &… | 6 |
| AZD-8055 & MK-1775 | 6 | mTOR-specific | p53/ wee1 | 6 |
| BI-2536 & BRD-7389 | 6 | Polo-like kinase | p90 RS6K | 6 |
| BI-2536 & Dasatinib | 6 | Polo-like kinase | Abl & Src | 6 |
| BYL-719 & Flavopiridol | 6 | PI3Kalpha | CDK | 6 |
| Dasatinib & GSK1120212 | 6 | Abl & Src | MEK1 & 2 | 6 |
| Dasatinib & PF-431396 | 6 | Abl & Src | FAK/PYK2 | 6 |
| Flavopiridol & Simvastatin | 6 | CDK | HMGCoA Reductase | 6 |
| Foretinib & MK-1775 | 6 | MET & AXL &… | p53/ wee1 | 6 |
| Foretinib & SB225002 | 6 | MET & AXL &… | CXCR2 | 6 |
| Foretinib & Vorinostat | 6 | MET & AXL &… | HDAC | 6 |
| GDC-0941 & SN-38 | 6 | PI3K | Topoisomerase | 6 |
| Gemcitabine & MLN-4924 | 6 | nucleoside analog | Neddylation | 6 |
| GSK1120212 & MK-2206 | 6 | MEK1 & 2 | AKT1-3 | 6 |
| JQ1 & MLN-8237 | 6 | Bromodomain | Aurora Kinase | 6 |
| JQ1 & Pemetrexed | 6 | Bromodomain | folate agent | 6 |
| JQ1 & PF-431396 | 6 | Bromodomain | FAK/PYK2 | 6 |
| MK-1775 & SN-38 | 6 | p53/ wee1 | Topoisomerase | 6 |
| MLN-4924 & MLN-8237 | 6 | Neddylation | Aurora Kinase | 6 |
| MLN-4924 & Oligomycin | 6 | Neddylation | OxPhos | 6 |
| MLN-4924 & Pemetrexed | 6 | Neddylation | folate agent | 6 |
| MLN-8237 & SN-38 | 6 | Aurora Kinase | Topoisomerase | 6 |
| Paclitaxel & SB225002 | 6 | microtubule | CXCR2 | 6 |
| Paclitaxel & SN-38 | 6 | microtubule | Topoisomerase | 6 |
| Simvastatin & YM155 | 6 | HMGCoA Reductase | Survivin | 6 |
| SN-38 & YM155 | 6 | Topoisomerase | Survivin | 6 |
a
Combinations with six or more observations meeting filtering and thresholding criteria described in the text are listed.
b
Nominal “Targets” listed for each agent were curated manually from the research literature, may not apply to all drug doses, and are not all-inclusive.
c
Combinations with an identical number of observations meeting criteria have identical ranks and are ordered alphabetically.